Business Wire

CA-GCA

9.5.2016 10:31:34 CEST | Business Wire | Press release

Share
GCA Savvian and Altium Sign Definitive Merger Agreement to Form GCA

GCA Savvian Corporation, a premier global investment bank (TSE: 2174), and Altium, a leading international mid-market financial advisory group, today announced that they have entered into a definitive merger agreement. This combination creates a leading independent international investment bank focused on growth companies with an extensive global network, cross-border capability and track record of industry-shaping transactions. GCA will operate under the names GCA Altium in Europe and GCA in the United States and Asia.

Upon the completion of the transaction, GCA will be a leading global pure play advisory business with a focus on growth companies and the 7th largest listed M&A advisory firm in the world, with approximately $200 million in advisory revenues, approximately 370 staff, 300 of whom are experienced M&A bankers and growth company experts, offices in 14 locations in 10 countries around the globe, and more than 315 completed transactions over the last three years.

The combination brings together two extremely complementary businesses with a strong strategic and cultural fit. Together, GCA Savvian and Altium focus on growth companies and hold top positions in key growth sectors, particularly technology, digital media, telecommunications, eCommerce and retail. There are substantial opportunities for synergies between the two businesses, which will result in increased international reach to form outstanding cross-border capabilities and a truly global network in key markets. GCA will have offices in Tokyo, San Francisco, New York, Osaka, Shanghai, Singapore, Mumbai, London, Manchester, Frankfurt, Munich, Zurich, Milan and Tel Aviv.

“We are pleased to announce our merger with Altium. By bringing together these two established companies, we are creating a new global leader in our field,” said Aki Watanabe, Representative Director of GCA Savvian Corporation. “This combination will increase the scale and geographic reach of the firm – positioning GCA as the pre-eminent global investment bank focused on growth companies with a particular strength in technology.”

Phil Adams, CEO of Altium, said: “Our merger with GCA Savvian marks a key and exciting step in our growth strategy. Now, more than ever before, our clients are looking for integrated international coverage and this merger will enable us to provide the best possible service to our clients.”

The merger further increases the firm’s leading volume of cross border deals and will drive revenue growth while also further strengthening its presence within the private equity and venture capital community.

Both companies have built strong, reputable brands through their track records, highly experienced and respected management teams, independent, client-centric advice and transaction execution expertise.

GCA will continue to provide its clients with a broad range of investment banking services including M&A, capital markets, capital raising services for fund managers, debt advisory and private capital raising.

Under the terms of the agreement, which has been unanimously approved by the Boards of Directors of both GCA Savvian and Altium, Altium will merge 100% of its shares into GCA. GCA will be governed by a Board of Directors that includes, Geoffrey Baldwin, Todd Carter, Richard Kramlich, and Mark McInerney from the USA, Jiro Iwasaki, Isao Okubo, Hiroaki Ota, Masatake Yone, and Akihiro Watanabe (Representative Director) from Japan and Phil Adams, Alexander Grünwald and Sascha Pfeiffer from GCA Altium in Europe.

The transaction is subject to regulatory approval and other customary closing conditions and is expected to close early in the second half of 2016.

About GCA Savvian

GCA Savvian is a premier global investment bank serving growth companies through a range of services that include mergers and acquisitions, capital markets, private funds and restructuring advisory. GCA Savvian professionals deliver deep expertise in a range of industries such as technology, media & digital media, communications, healthcare, financial institutions, industrials, and e-commerce. The firm has offices in Tokyo, San Francisco, New York, London, Mumbai, Osaka, Shanghai, and Singapore.

About Altium

Altium is a leading international mid-market financial advisory group, providing M&A, debt and corporate finance advice to companies, private equity firms and entrepreneurs. Established more than 30 years ago, Altium is a truly independent, employee-owned company. Today, the firm operates offices in London, Manchester, Frankfurt, Munich, Zurich, Milan and Tel Aviv. Altium has established itself as a global leader in mid-market private equity and debt advisory deals, as well as the Digital, Media & Internet, Technology & Telecom, Consumer & Retail, Healthcare, Industrials, Business Services and Energy sectors. Altium is dedicated to finding the best possible tailored solutions for its clients through its vast network, profound expertise, service and solution-oriented approach, and independent perspective.

Contact:

GCA
James M. Kadleck, 415-318-3681
jkadleck@gcasavvian.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release

£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release

Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye